Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor…

Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, Briere DA, Benson C, Nauck MA, Haupt A. Diabetes, Obesity and Metabolism 2020

Document identifier
CEI-BR-109
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, Briere DA, Benson C, Nauck MA, Haupt A
Title
The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists
Source
Diabetes, Obesity and Metabolism
Year
2020
Volume, issue, pages
22(10):1886–1891
Digital object identifier
10.1111/dom.14110
PubMed identifier
32519795
Record type
Journal article
Institute identifier
CEI-BR-109

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: TirzepatideCompound monograph
1 citing document.

§1.3Subject tags

tirzepatide gastric-emptying pharmacokinetics

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.